Ethic Inc’s Ginkgo Bioworks DNA Stock Holding History

Ethic Inc’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-532	Closed	-$35.9K	–	1097
2023 Q4	$35.9K	Sell	532 -389	-42%	-$23.8K	﹤0.01%	1041
2023 Q3	$66.7K	Sell	921 -2,802	-75%	-$224K	﹤0.01%	993
2023 Q2	$277K	Buy	3,723 +277	+8%	+$16.4K	0.01%	809
2023 Q1	$182K	Buy	3,446 +2,713	+370%	+$172K	0.01%	904
2022 Q4	$49.5K	Sell	733 -198	-21%	-$18.2K	﹤0.01%	889
2022 Q3	$116K	Buy	+931	New	+$111K	0.01%	762

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ethic Inc's DNA Position: Q1 2024 in Review

Ethic Inc sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 532 shares — an estimated $35.9K sold.

Ethic Inc first reported a position in DNA in Q3 2022 and held it in 6 quarters. The position peaked at $277K in Q2 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

Ethic Inc reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
Ethic Inc sold 532 Ginkgo Bioworks shares in Q1 2024, an estimated $35.9K.
Ethic Inc first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 6 quarters.
Ethic Inc's Ginkgo Bioworks position peaked at $277K in Q2 2023.
342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on Ethic Inc's 13F filing for Q1 2024, filed 13 May 2024.